EP1786262A1 - Methods for the production of improved live stocks and disease models for therapeutic research - Google Patents

Abstract

The application relates to a method of providing an oocyte capable of producing a mutated non-human animal, the method comprising treating an oocyte with a mutagen in vitro; and contacting said oocyte with a sperm cell for fertilization. The application also relates to a method of providing an embryo capable of producing a mutated non-human animal comprising treating an oocyte with a mutagen in vitro; contacting said oocyte with a sperm cell for fertilization and allowing the resulting zygote to develop into an at least 4-cell stage embryo or a non-human animal capable of sexually reproducing.

Description

Methods for the Production of Improved Live Stocks and Disease Models for

Therapeutic Research

Background of the Invention

During the last decades, the mouse has become the most popular animal in which to generate model systems reflecting human diseases. As such disease models exhibit disease symptoms, they can be used to further investigate diseases, which leads to a more comprehensive understanding of the diseases and opens the field for developing new therapeutic concepts. In addition, such disease models are useful to study the effect of known pharmaceutical compounds as well as to screen for potentially novel compounds. For example, Harvard scientists made a genetically engineered rodent, called OncoMouse^® (see US Patent 4,736,866), carrying a gene that promotes the development of various human cancers. This animal model is a very well recognized tool for developing treatments and cures of human cancer.

Recently, larger domestic animals are proving to be more and more valid research and disease models due to their anatomical and physiological similarities to humans. For example, the pig has proven to be a good model for pancreatic cancer (Kurahashi et al., 2004) and kidney stone disease (Mandel et al., 2004). Furthermore, the pig is a good ischemia model (Hughes GC et al., 2004).

In addition, larger domestic animals may provide transplant organs like heart, liver, and kidney. Due to the problem of donor rejection, these animals need to be modified to overcome immunological problems prior to their use to generate organs. In pigs, it has been found that the donor rejection is due to sugar-based molecules called alpha- 1,3-galactosylated moieties located at the surface of pig cells. Lai et al. (2002) described a knockout in pig of one allele of the gene GGTAl, which encodes the enzyme alpha- 1,3 -galactosyl transferase. This transferase is involved in transferring the sugar molecules onto the pig cell surface. Phelps et al. (2003) described a double-knockout in pig, the second allele being silenced by a natural mutation in exon 9. Thus, the direct and reliable provision of pigs with an inactivation of these genes will render the pig an attractive organism to produce transplant organs for humans. Moreover, the modification of a particular gene's normal function in non- human animals, e.g., domestic/farm animals, for economic or medical purposes is increasingly important. For example, Myostatin, or GDF8 (Growth Differentiation Factor 8), a member of the transforming growth factor-beta superfamily plays a role in the control and maintenance of skeletal muscle mass (Gonzalez-Cadavid, 1998). This information encouraged scientists to develop methods for inhibiting the expression of the myostatin gene or the activity of the protein. A method to inhibit myostatin in order to promote muscle growth and weight gain is disclosed in US Patent Application 2004/0030114. US Patent Application 2002/02127234 discloses an immunoconjugate comprising a full-length myostatin polypeptide linked to a carrier as vaccine. US Patent Application 2003/0140356 discloses myostatin mimetics, binding to the myostatin receptor.

In addition, mice ("Mighty mouse") and cattle ("Belgium Blue cattle") with inactivating mutations of myostatin have marked muscle hypertrophy. US Patent 5,994,618 discloses transgenic mice carrying a disrupted endogenous myostatin gene. Transgenic mice were significantly larger than wild-type animals and displayed a large and widespread increase in skeletal muscle mass. US Patent 6,103,466 discloses, e.g., cattle myostatin polynucleotide sequences with an 11 bp deletion, resulting in a non-functional myostatin protein. Additional mutations in cattle, nt419(del7-inslθ), Q204X, E226X, and C313Y, resulting in double-muscleing are described in US Patent Application 2003/0129171 and in European Patent Application EP 1 002 068. Thus, the generation of animals with increased body mass is of economic advantage to the farmers. The development of larger transgenic non-human animals, e.g., domestic/farm animals, is, however, currently very expensive. Up to date, the major problems are long time periods to produce such animals, low success rate, and high costs due to the lack of reliable methods in higher species.

The above examples demonstrate that the increasing knowledge of disease- causing genes and the increasing understanding of gene function require more efficient methods directed to the provision of organisms carrying mutations in various genes.

One possibility to efficiently generate mutants is via physical and chemical mutagenesis. A well-known chemical mutagen in this respect is, e.g., N-ethyl-N- nitrosourea (ENU). ENU randomly ethylates DNA, which may subsequently result, e.g., into a non-conservative nucleotide exchange (point mutation) during DNA replication in the next cell cycle. Such subtle DNA mutation may further result in a corresponding amino acid exchange. Consequently, ENU mutagenesis does not introduce foreign DNA into the recipient's genome and will not implicate positional effects like those known from random transgene integration.

In mice, the introduction of point mutations in male germ cell DNA is currently performed by intraperitoneal ENU-injection. The mutagenized mouse or its offspring is analyzed for an aberrant phenotype, e.g., mutation identification may be performed with a screen of phenotypic alterations prior to mutation identification in a gene of interest. Alternatively, the injected animal or its offspring is analyzed for a mutation in a gene of interest on a molecular basis without prior observation of any phenotype (see US Patent 5,994,075). Embryonic stem (ES) cells may also be subjected to ENU mutagenesis, as described in US Patent 6,015,670, WO 97/44485, and WO 99/67361.

ENU mutagenesis has also been described for other species, e.g.,

Drosophila melanogaster (Vogel and Natarajan, 1995), ascidians (Moody et al., 1999), or zebrafish (Grunewald and Streisinger, 1992). In contrast to mouse, ascidians and zebrafish have been treated with ENU by direct incubation of the organism in ENU (e.g., Moody et al., 1999). Grunewald and Streisinger (1992) reported in vitro ENU mutagenesis of freshly isolated zebrafish sperm and subsequent mixing with freshly collected eggs for fertilization.

Compared to known transgenic methods, e.g., ES-cell mediated gene transfer (Bradley et al., 1984; Capecchi et al., 1989), DNA microinjection (Betsch et al., 1995), nucleus transfer in combination with an initial manipulation of the donor nucleus by a transgene insertion (Schnieke et al., 1998) or Lenti-virus induced gene transfer (Hofman et al., 2004), ENU mutagenesis has the advantage of introducing particular point mutations, i.e., subtle DNA modifications without introducing foreign DNA (for example antibiotic selection marker gene or viral genetic material) into the recipient's genome. The generation of transgenic animals further poses the risk that the transgene may integrate within an endogenous gene (undesirable insertional mutation) with a possible loss of host gene function or other positional effects due to random integration, e.g., inappropriate transgene expression. Transgenic farm animals produced by known transgenic methods are classified as genetically modified organisms (GMO) with subsequent restrictions. Over the last three years many countries, including Germany, France and the UK, signed the "Cartagena Protocol on Biosafety". The Protocol specifically regulates the handling of GMO for agricultural use. ENU-modified animals are not classified as GMO.

As mentioned above, ENU mutagenesis is useful for the generation of hypomorphic, hypermorphic and neomorphic alleles of a gene in a model organism, e.g., by single amino acid substitutions. This may be desirable to create a model organism for, e.g., a human trait or disease in which gene function is modified rather than destroyed.

Furthermore, the ENU method also allows for the identification of an allelic series of mutations in a gene of interest. These mutations might be desirable mutations that merely modify gene function (e.g. hypomorphic or hypermorphic alleles that express the gene with reduced or increased efficiency) or that give rise to a new trait in the animal (e.g. by generating dominant neomorphic alleles which result in a gain-of-function or loss-of function). The usefulness of identifying an allelic series of alterations in a gene of interest was illustrated in the human peroxisome proliferator-activated receptor gamma (PP ARγ) gene (Barroso et al., 1999). A dominant-negative V290M mutation and a dominant- negative P467L mutation in the receptor's ligand-binding domain, respectively, is associated with an unusual syndrome of severe insulin resistance, early onset diabetes and hypertension. Therefore, a new subtype of dominantly inherited type 2 diabetes was described, due to defective transcription factor function of PP ARγ. The underlying point mutations provided the first time evidence for the direct involvement of PP ARγ in the control of insulin sensitivity, glucose homeostasis and blood pressure in man (Barroso et al., 1999).

Current methods of ENU mutagenesis, e.g., in mice, are not necessarily appropriate for higher vertebrates, e.g., domestic/farm animals. ENU mutagenesis in mice is performed as intraperitoneal injection of ENU into male mice (see Example 1 of WO

2004/020619), using defined mg/kg dosages of ENU, which are injected once or several times. Due to ENU-induced sterility, the earliest date at which male mice can be mated to females is fifty days after the final ENU injection, when fertility starts to overcome the ENU-induced sterility. The subsequent Gl offspring represents a "living archive", which is subject to phenotypic and nucleic acid analyses, in order to identify a mutation in a gene of interest.

Intraperitoneal application of ENU to larger farm/domestic animals, for example male cattle, will, however, be associated with relatively high costs and low efficiency. For cattle with a reproduction cycle of 12 months and on average 1 offspring per pregnancy, it would require a long time and a lot of space to generate the above- mentioned living archive. In addition, dosage testing and optimization may take some time, since intraperitoneal ENU injection may imply lethality of the ENU recipient at certain doses. Furthermore, large amounts of ENU would be required. For a bull with up to 700 kg body weight approximately 63 g of ENU need to be injected in a single dosage. If it survived injection, the period of sterility of a bull may last up to several months.

As an alternative to the maintenance and analysis of the aforementioned "living archive" of Gl ENU-mutagenized mice, another method for identifying a mutation in a gene of interest comprises the parallel isolation of a tissue sample (for the further isolation of nucleic acid samples) and of sperm cells from all Gl male offspring. Cryopreservation is established for many species, e.g., for mouse (Nagakata et al., 1993), cattle (Foote and Kaprotht, 2002), carp (Magyary et al., 1996) and camel (Deen et al, 2003). The tissue sample and sperm cells are subjected to freezing, representing a "frozen archive". The step of replacing a "living archive" of up to several thousand Gl offspring with a "frozen archive" reduces costs and increases the speed in analysis and generation of mutant animals: nucleic acid samples are used for the analysis of a mutation in a gene of interest by industrial HTS screening of the nucleic acids. Once a desired mutation is identified, the corresponding sperm cells are thawed and subsequently used for in vitro fertilization. The resulting embryos are implanted into a foster mother's uterus to generate offspring. The offspring is carrying the previously identified mutation in a gene of interest, according to Mendelian rules.

However, sperm of certain animal species, especially those that do not fertilize ex vivo, do not always tolerate a freezing procedure well, which may make it difficult to establish an archive that is representative of large number of mutations.

There is a need in the art for methods of producing mutated non-human animals, which avoid one or more of the above-mentioned drawbacks, or provide improvements in this regard, or which represent valuable alternatives to the prior art methods.

Summary of the Invention

The invention is inter alia directed to a method of generating mutated animals using oocyte mutagenesis in combination with subsequent fertilization with a sperm cell, e.g., FVF. With this method, it is, e.g., possible to efficiently determine the appropriate dosage regime regarding a particular mutagen in vitro, resulting in a substantial saving of time, costs and animals. The methods of the present invention are applicable to many species. In addition, the mutagenesis on oocytes provides the possibility to efficiently mutate every gene in a given sexually reproducing organism.

More specifically, the present invention provides in a first aspect a method of providing a fertilized mutated oocyte comprising:

(a) treating an oocyte with a mutagen in vitro;

(b) contacting the oocyte obtained in step (a) with a sperm cell for fertilization.

In order to provide an embryo capable of producing a mutated non-human animal, the zygote resulting from step (b) above may then be allowed to develop into:

(i) an at least 4-cell stage embryo; or

(ii) a non-human animal capable of sexually reproducing.

Further, the fertilized oocyte, the embryo or the one or more germ cells, e.g., sperm cells or oocytes, of the non-human animal obtained in steps (b), (b)(i) or (b)(ii) above, may be stored; or the non-human animal obtained in step (b)(ii) above can be maintained.

In one embodiment, the sperm cells used to fertilize the oocyte in step (b) are not treated with a mutagen. However, sperm cells treated with a mutagen, e.g., a mutagen selected from the mutagens mentioned hereinafter as suitable in the practice of the present invention, may likewise be used.

The method may further comprise the isolation of one or more cells, preferably at least two cells, of the embryo or the non-human animal, preferably isolation prior to storing.

The method may additionally further comprise the screening of a nucleic acid sample derived from one or more cells, preferably at least two cells, of the embryo or the non-human animal produced in step (b) for the presence of a mutation in a gene of interest.

The method may further comprise the step of assigning said mutation to the corresponding embryo or the one or more germ cells of the non-human animals stored, or to the non-human animal maintained as described above.

In another aspect, the invention provides a method of producing a non- human animal from the stored oocyte, embryo or germ cells of the non-human animal. The method of producing a non-human animal may comprise the reimplantation of such an embryo, preferably a morula or a blastocyst stage, into a non-human animal foster mother. In case the stored germ cells are sperm cells, the method of producing a non-human animal further comprises the in vitro fertilization of an oocyte with said one or more sperm cells of the non-human animal and the subsequent reimplantation of the resulting embryo into a non-human animal foster mother or artificial insemination with said one or more sperm cells of the non-human animal.

The invention further provides a method, wherein step (b) comprises contacting a plurality of oocytes obtained in step (a) with sperm cells for fertilization. The resulting zygotes can then further be allowed to develop into at least 4-cell stage embryos or non-human animals capable of sexually reproducing. The plurality of embryos or germ cells of non-human animals obtained in step (b) can then be stored as described above, or the plurality of the non-human animals obtained in step (b) can be maintained.

The invention further provides an archive comprising the stored oocytes, embryos or germ cells of the non-human animals described above. The invention also provides a method of producing a non-human animal, wherein said method further comprises the breeding of the non-human animal(s) produced and/or maintained by the methods as described herein to produce a plurality of offspring.

Brief Description of the Figures

Figure 1 depicts a flow chart, describing two alternative embodiments

A and B of the method of the invention for generating non-human animals from mutagenized oocytes.

A. Mutagenized oocytes are subject to In Vitro Fertilization (FVF). The resulting zygotes are allowed to develop into the morula or blastocyst stage of embryonic development (morulas/blastocysts) before blastomer sample dissection from these embryos. Blastomeres' nucleic acid is used for mutation identification in a gene of interest. Dissected embryos are either cryopreserved (Embryo "frozen archive") prior to mutation identification on nucleic acid isolated from the blastomer samples (A-I) or directly transferred into foster mothers (Embryo transfer) after the mutation identification on nucleic acid isolated from the blastomer samples (A-2). Gl offspring is delivered. In A-I, mutation identification will select embryos carrying mutations in a gene of interest. The selected embryos, which were stored in the embryo "frozen archive", are subjected to embryo transfer to generate Gl offspring. Subsequent offspring G2 and Gn (where "n" means any offspring following G2 offspring) is generated. In A-2, the Gl embryo is selected based on the results of the mutation identification on nucleic acid isolated from the blastomeres (bypassing the "frozen archive" and the DNA "archive") to produce Gl offspring. Offspring carrying a mutation in a gene of interest, the mutation having been verified on nucleic acid from an animal's tissue sample, is selected for further breeding and generating G2 and Gn offspring.

B. Mutagenized oocytes are subject to In Vitro Fertilization (IVF) and subsequent embryo transfer. Pregnant animals will deliver Gl offspring (Gl Offspring "living archive"), which is subject to tissue sample dissection (for DNA collection or "archive") and optionally isolation of germ cells. Germ cells are collected to establish a germ cell "frozen archive". The DNA of the tissue samples is analyzed for mutations in a gene of interest (mutation identification). Once a mutation in a gene of interest is identified, corresponding animals from the Gl offspring are selected for further breeding of G2 and Gn offspring (B-I). Alternatively, once a mutation in a gene of interest is identified, corresponding germ cells are selected for generating G2 and Gn offspring (B-2).

Embryos, nucleic acids derived from tissue samples, and germ cells from offspring delivered by methods A and B are collected for establishing frozen archives (embryo "frozen archive", "DNA archive", and germ cell "frozen archive", respectively).

Detailed Description of the Invention

Definitions

The terms "organism" or "organisms" refer to multicellular eukaryotes that undergo development from an embryonic stage to an adult stage. Accordingly, this includes vertebrates and invertebrates, which fall within the term "animal", as well as plants and fungi. The invention is useful with respect to animals, such as insects, nematodes, fish, such as salmon; or mammals, for example ungulates, such as pig, cattle, goat, or sheep; or odd-toed ungulates, such as horse; or rodents, such as mouse or rat.

The terms "treating an oocyte with a mutagen" or "treating oocytes with a mutagen" as used herein refers to the contact or exposure of a single oocyte or a population of oocytes, respectively, in vitro with a mutagen of choice.

The term "phenotype" as used herein refers to one or more morphological, physiological, behavioral and/or biochemical traits possessed by a cell or organism that result from its genotype.

Thus, the term "alteration of the phenotype" as used herein refers to a non- human animal of the present invention displaying one or more readily observable abnormalities compared to the wild-type animal. In a preferred embodiment, an animal obtained via the methods of the invention shows at least 1, at least 2, at least 3, or at least 4 abnormal phenotypic features selected from any of the above categories. In another preferred embodiment, the animal shows a loss of function phenotype. In yet another preferred embodiment, the animal shows a gain of function phenotype. The term "desired phenotype" as used herein refers to phenotypic alterations that are favorable for medical or economic reasons, such as exhibiting human disease symptoms, disease resistance in farm animals, immunological tolerance, or modulation of gene function.

The term "capable of sexually reproducing" as used herein refers to a non- human or non-human animals capable of sexually reproducing via gamete fusion, that is the fusion of a sperm and an egg cell.

The term "mature sperm cells" or "spermatozoa" means sperm cells isolated from cauda epidydimis or vas deferens.

The terms "Gl offspring", "G2 offspring", and "Gn offspring", as used in the present invention, mean the first (Gl, generation 1), second (G2, generation 2), and any subsequent offspring generations (Gn, n=any offspring generation following G2 offspring), generated from initial fertilization of an in vitro mutagen-treated oocyte with a sperm cell. Due to the kind of mutagenesis contemplated herein, the Gl offspring is chimeric with respect to the induced mutations.

The terms "chimeric" or "chimera" as used herein mean that the developing embryo starting from the two cell embryo will be a 50% chimera with approximately 50% of its cells being genetically different from the other 50% of its cells.

The term "embryo capable of producing a mutated non-human animal" as used herein refers to an at least 2-cell stage embryo that is capable of developing into a sexually reproducing animal as described herein, e.g., upon (re)implantation into a foster mother for development.

The term "oocyte capable of producing a mutated non-human animal" as used herein refers to oocytes, which are capable of being fertilized by a sperm cell in vitro, e.g., via IVF, and further developing into a non-human animal under appropriate conditions, e.g. upon reimplantation into a suitable foster mother.

The term "nucleic acid" as used herein, refers to DNA, such as genomic DNA, or cDNA, but also RNA. The term "gene" as used herein refers to a segment of DNA which may be transcribed into RNA, and which may comprise an open reading frame, intronic sequences, and also includes the regulatory elements which control expression of the transcribed region. Therefore, a mutation in a gene may occur within any region of the DNA which is transcribed into RNA, or outside of the open reading frame and within a region of DNA which regulates expression of the gene (i.e., within a regulatory element). In diploid organisms, a gene is composed of two alleles.

The term "mutation" as used herein refers to a difference in the nucleotide sequence of a given gene or regulatory sequence from the naturally occuring or normal nucleotide sequence, e.g., a single nucleotide alteration (deletion, insertion, substitution), or a deletion, insertion, or substitution of a number of nucleotides. The term "mutation" also includes chromosomal rearrangements. "Introduced mutation" as used herein means a mutation introduced by chemical or physical mutagens.

The terms "tissue sample" or "cell biopsy" as used herein, mean a multicellular sample of an organism's tissue or organ or a single cell sample, the sample having been isolated by biopsy techniques, where the organism is in any stage of development from embryonic developmental stages to adult stage. A tissue sample may comprise a single or one or more, preferably two, blastomer(es) dissected from a morula or blastocyst embryonic developmental stage; or a piece of an organ, e.g., liver, isolated from a non-human animal, e.g., from birds, fish or mammals; or a piece of tissue, e.g., tail, isolated by tail clipping from a non-human animal, e.g., from rats, mice, cattle or pig.

The term "archive" as used in the present invention refers to a collection of samples from different sources stored under conditions suitable to preserve the integrity of the material. The collection can encompass nucleic acids of tissues, tissue or cell samples of a non-human organism or an embryonic developmental stage as well as embryos or germ cells or the non-human animal itself.

The term "non-transgenic" as used herein refers to an organism that does not carry in its genome a heterologous nucleic acid segment that is artificial or derived from (an)other organism(s) in respect of its sequence. The term "blastomer" as used herein refers to any cell resulting from dissection of an embryo.

The term "morula" as used herein refers to a developmental stage of an embryo, where it consists of approx. 4 to 16 cells.

The term "blastocyst" as used herein refers to a developmental stage of an embryo, where it consists of 16 to approx. 300 cells. It is covered in a layer of trophoblast cells, which eventually form the placenta.

Methods of the Invention

We inter alia describe a method of providing an embryo or an oocyte capable of developing into an at least 4 cell stage embryo, or a mutated non-human animal. This method comprises the treatment of an oocyte with a mutagen, e.g., a chemical or physical mutagen, preferably ENU (see Example 1). The method further comprises contacting said oocyte with a sperm cell (or a plurality of sperm cells) for fertilization. After fertilization, the replication of the oocyte DNA treated, e.g., with ENU prior to fertilization, produces two different DNA molecules in the diploid zygote. One molecule will carry a mutation as the replication mechanism will introduce with a certain probability a different base at the position of the altered, e.g., ethylated and thereby modified base. Hence, a mutation is introduced in one of the two oocyte DNA molecules after the first mitotic duplication. The co-duplicated sperm DNA will not carry the mutation (although it may carry other mutations introduced, e.g., via the prior treatment of the sperm cell(s) with a mutagen). With the division of the zygote a two-cell embryo is produced, one cell carrying the copy of the sperm (paternal) DNA and one copy of the egg (maternal) DNA. Due to the introduced point mutation, one cell differs genetically from the other cell. As a consequence, the developing embryo will be a 50% chimera with eventually approximately 50% of its cells being genetically different with respect to the above mutation from the other 50% of its cells with respect to the above mutation. The method further allows the resulting zygote to develop into an at least 4-cell stage embryo or into a non-human animal capable of sexually reproducing; and storing the embryo or the one or more germ cells of the non-human animal (see Example 7). The oocyte treated with a mutagen may be derived from the same or a different non-human animal species compared to the non-human animal species from which the sperm cellis derived. The sperm and the oocyte used for the contacting step may be derived from a wild-type non-human animal. They may, however, also be derived from a transgenic non-human animal which has a selected phenotype compared to the wild-type animal and is intended to be subjected to further mutagenesis to alter, e.g., improve said phenotype.

In one embodiment, said fertilization comprises in vitro fertilization (IVF) and said resulting zygote is allowed to develop into an at least 4-cell stage embryo (see Example 2). This embryo is dissected and one or more cells, preferably at least two cells, e.g. blastomeres or trophoectodermal cells of the embryo, are used to isolate a nucleic acid sample, which may be screened for the presence of a mutation in a gene of interest (see Examples 3 and 6). The remaining embryo, e.g., a morula or a blastocyst, preferably an at least 2-cell embryo, is stored, preferably frozen. Upon screening of the nucleic acid sample for a mutation in a gene of interest, the corresponding stored embryo is assigned to the identified mutation. The assigned embryo is then further used to produce a non-human animal from the embryo according to the methods described herein (see, e.g., Example 8). This step may comprise the reimplantation of the embryo, preferably a morula or a blastocyst stage, more preferably an at least 2-cell embryo, into a non-human animal foster mother.

In yet another embodiment, one or more cells, preferably at least two cells, of the embryo are isolated and nucleic acid samples thereof are analyzed for a mutation in a gene of interest. The corresponding embryo is directly used for further breeding without freezing (see, e.g., Example 8). The resulting non-human animal carrying the mutation in the gene of interest may be further bred to produce a plurality of offspring generations carrying said mutation.

In another embodiment, said fertilization step comprises IVF and the subsequent development of a non-human animal capable of sexually reproducing, as mentioned herein (see Example 9). One or more cells are isolated from the non-human animal capable of sexually reproducing. The cells are isolated from an organ, e.g., liver, or a tissue, e.g., ear or tail. Also isolated are one or more germ cells, e.g., spermatogonia, spermatides, mature sperm cells, or oocytes. The one or more germ cells are stored, e.g., frozen, or kept in an appropriate culture medium. The one or more tissue or organ cells may be isolated prior to or after the isolation and freezing of said germ cells.

A nucleic acid sample is isolated from said one or more tissue or organ cells, which is screened for a mutation in a gene of interest (see Example 6). Upon screening of the nucleic acid sample, the corresponding stored one or more germ cells are assigned to the identified mutation. The assigned one or more germ cells, e.g., spermatogonia, spermatides, mature sperm cells, or oocytes, are further used to produce a non-human animal. This step comprises, e.g., the IVF of an oocyte, e.g., a wild type oocyte, with stored mature sperm cells, and the subsequent reimplantation of the resulting embryo into a non-human animal foster mother. An alternative is the artificial insemination using said stored sperm cells. Alternatively, this step comprises the IVF of a stored oocyte with mature sperm cells, e.g., wild type sperm cells, and the subsequent reimplantation of the resulting embryo into a non-human animal foster mother according to the methods described herein (see, e.g., Example 1).

In yet another embodiment of the above method, one or more tissue or organ cells are isolated from the non-human animal and their nucleic acid samples are analyzed for a mutation in a gene of interest. The non-human animal is maintained for further breeding without storing, e.g., freezing, of one or more germ cells. The resulting non-human animal carrying the mutation in the gene of interest may be further bred to produce a plurality of offspring generations carrying said mutation.

In one embodiment, the resulting non-human animal as described herein may be non-transgenic. In a further embodiment, said non-human animal is a vertebrate, e.g., a mammal, a fish, or a bird. Preferably, said mammal is a mammal selected from the group of mouse, rat, hamster, rabbit, cattle, pig, guinea pig, sheep, goat, horse, camel, dog, cat, monkey, e.g., rhesus macaque, baboon, orang-utan, and chimpanzee. Said fish is preferably selected from the group of fish consisting of salmon, trout, tilapia, carp, catfish, medaka, zebrafish, loaches, goldfish, and pikes. Said bird is preferably selected from the group of chicken, duck, turkey, pigeon, goose and Japanese quail.

In another embodiment of the invention, the method comprises contacting and fertilizing a plurality of oocytes and allowing the resulting zygotes to develop into at least 4-cell stage embryos or non-human animals capable of sexually reproducing. The method may furthermore comprise storing a plurality of the resulting embryos or germ cells of the resulting non-human animals, e.g., by freezing or storing in an appropriate culture medium or maintaining the non-human animals obtained from the developing zygote, for, e.g., further breeding.

Yet another embodiment of the invention is an archive comprising the stored, e.g., frozen embryos or one or more germ cells of the non-human animals.

Another embodiment of the invention is an archive comprising one or more cells, preferably at least two cells, from each of a plurality of embryos prepared by the method of the invention, e.g., from at least 4-cell stage embryos, or comprising one or more cells from the non-human animals capable of sexually reproducing prepared by the method of the invention, e.g., cells from their tissue or organs.

Another embodiment of the invention is an archive comprising nucleic acid samples isolated from the above-mentioned one or more cells, preferably at least two cells, from the embryos, e.g., from the at least 4-cell stage embryos, or from the above- mentioned one or more cells from the non-human animals capable of sexually reproducing, e.g., cells from their tissue or organs.

Yet another embodiment of the invention is an archive comprising the maintained non-human animals that developed from the zygotes resulting from the fertilization of the oocytes treated with a mutagen in vitro.

A further embodiment is a plurality of non-human animals, wherein said animals are produced by the plurality of stored embryos or the plurality of stored germ cells of the invention.

Mutagenesis

The invention encompasses mutagenesis of oocytes in vitro. Suitable mutations and mutagens are described below.

1. Type of DNA Mutations

Mutations in the DNA may comprise large lesion mutations, e.g., chromosomal breaks, rearrangements, and large insertions or deletions (in the order of kilobases); small lesion mutations, e.g., cytogenetically visible deletions within a chromosome; and/or subtle mutations, e.g., point mutations, such as conservative or non- conservative substitutions, insertions, and small deletions (in the order of several-tens of bases).

The latter category of mutations is preferred in the present invention. Also preferred are substitution mutations, e.g., non-conservative substitutions. Moreover, mutations that do not result in the complete deletion of the gene of interest are preferred, e.g., mutations within the gene or its regulatory sequences.

2. Chemical Mutagenesis and Mutagens

Chemical mutagens may be classified by the chemical modification, which they induce, e.g., alkylation, cross-linking, intercalation, etc.

Useful chemical mutagens according to the invention comprise N-ethyl-N- nitrosourea (ENU), Methylnitrosourea (MNU), Procarbazine hydrochloride (PRC), Triethylene melamine (TEM), Acrylamide monomer (AA), Chlorambucil (CHL), Melphalan (MLP), Cyclophosphamide (CRP), Diethyl sulphate (DES), Ethyl methane sulphonate (EMS), Methyl methane sulphonate (MMS), 6-mercaptopurine (6MP), Mitomycin-C (MMC), Procarbazine (PRC), N-methyl-N-nitro-N-nitrosoguanidine (MNNG), N-nitrosodiethylamine (NDEA), Isopropyl methane sulphonate (iPMS), ³H₂O, Urethane (UR), Bleomycine, Nitrogen Mustard, Vincristine, Dimethylnitrosamine, 7,12- Dimethylbenz(a)anthracene (DMBA), Ethylene oxide, Hexamethylphosphoramide, Bisulfan, Acridine orange, Ethidium bromide, Proflavin, and ICR-191.

The chemical mutagens mainly cause single nucleotide alterations. For example ENU mainly causes adenosine to thymine or thymine to adenosine base changes, these changes representing roughly 45% of all base changes examined in the mouse germ line upon application of ENU (Noverskoe et al., 2000).

The induction of mutations with chemical mutagens is dependent on several parameters, e.g., the type, dose, and the mode of delivery of the mutagen or the frequency or type of mutations. The skilled person will be readily able to adjust the mutagenesis conditions for a given mutagen to the desired degree of mutation induction. ENU is a particularly preferred chemical mutagen of the present invention.

As to the frequency/dose, ENU offers the opportunity of obtaining a very large number of mutations in vivo, which gives tremendous power to ENU mutagenesis. For example, in mice it requires 1000 offspring (Gl mice) from a mating of ENU- mutagenized males to wild type females, to obtain a onefold statistical recessive mutation coverage of all mouse genes, which are approximately 30,000 to 35,000 genes (Hitotsumachi et al., 1985). This indicates the presence of 30-35 recessive mutations in each Gl mouse, which equals 1.5 to 1.8 mutations per chromosome.

Thus, in the present invention, a preferred mutation load of the Gl non- human animal is about 0.2 to 5, about 0.5 to 4, about 1 to 3, about 1.5 to 2, and about 1.5 to 1.8 mutations per chromosome.

Another preferred mutation load of the present invention is about one mutation per chromosome.

The presence of multiple recessive mutations in each Gl animal frequently led to the concern that a desired phenotype, based on the identified mutation in a gene of interest, may be confounded by the interaction of several mutations. This scenario is rather unlikely, however, based on the following example provided for a Gl mouse. In a mouse with a recombinational genome of 1453 centiMorgan (cM), 30-35 ENU-induced recessive mutations yield an average genetic distance between two functionally relevant mutations of 42-48 cM, indicating that adjacent mutations are almost certain to segregate in the next generation. The average distance between base-pair exchanges of 1,0-2,5 per Megabase

(Mb) is large enough so that, for every functional mutation, even the neighboring silent change can be segregated rapidly (Russ et al., 2002). Further breeding for mice homozygous for the mutation will subsequently further reduce the likelihood of such influence.

3. Physical Mutagenesis

Physical mutagens, e.g., radiation mutagenesis via gamma-radiation, X-ray radiation, or neutrons, may also be used in accordance with the invention. Such radiation mutagenesis causes DNA breakage. Due to DNA repair mechanisms, these DNA breaks may lead to regions on the DNA with large lesions, rearrangements, or deletions. In contrast, mutations induced by UV-light, which is likewise a suitable mutagen in connection with the present invention, are largely single nucleotide alterations. UV-light does not penetrate the animal but is generally useful for inducing mutations in cells in culture, e.g., ES cells or oocytes as in the present invention.

Pre Implantation Genetic Diagnosis (PGD)

1. General

Embryo biopsy and subsequent single-cell genetic analysis of the embryonic cells allow screening of embryos at the preimplantation stage of development. In humans, PGD techniques are being used to screen embryos for diagnosing genetic defects, which may lead to inherited diseases and other genetic conditions like postzygotic chromosomal abnormalities. Such abnormalities are likely to contribute to early pregnancy loss (Handyside and Delhanty, 1997). PGD routinely uses a single-cell biopsy for analysis.

In non-human animals, e.g., domestic/farm animals, PGD on single embryonic cells is widely used to determine the sex. The transfer of embryos of specific gender is economically beneficial and has herd management advantages. In addition, with the increasing effort of generating genetically altered non-human animals, e.g., domestic/farm animals, PGD gained importance for screening transgenic embryos in order to confirm their transgenic status for screening embryos to detect undesired genetic alterations (see in Nowshari and Brem, 2000a). Additionally, PGD may also be used to screen embryos for a desired genetic alteration.

2. Isolation of Cells

A tissue sample, e.g., one or more cells, preferably at least two cells, of the embryo of the invention, may be isolated at different embryonic developmental stages, e.g., from an at least 4-cell stage embryo (morula) or a blastocyst for PGD. The dissection of 1 or 2 blastomeres from an 8- to 16-cell stage embryo (morula) for PGD is described for many organisms, for example in mouse (Liu et al., 1993, Takeuchi et al., 1992) and in cattle (Bondioli et al., 1989, Bredbacka, 1994). A blastomer is removed and the embryo is subjected to cryopreservation (see Examples 3 and 7). Alternatively, a biopsy may be taken from the blastocyst stage, where the embryo contains up to 300 cells. With this method, a single cell or several cells may be removed without apparent detrimental effect, because blastocyst biopsy typically involves the preferential removal of the more accessible trophoectoderm cells, whereas the inner cell mass, that is destined to become the fetus, is not damaged (Gentry and Critser, 1995).

Tissue sample for PGD may also be isolated from one or more other cells of a non-human animal, e.g. tissues or organs of the adult organisms. A preferred tissue for rodents is, e.g., tissue from the ear or the tail of such rodent. A preferred tissue for birds is, e.g., the liver.

3. Primer Extension Preamplification (PEP)

The tissue sample, e.g. the one or more cells, preferably at least two cells, isolated from the embryo or the non-human animal, is used to prepare nucleic acid samples. Such nucleic acid samples may be DNA or RNA, preferably genomic DNA.

Since the amount of nucleic acid in a biopsy sample may be very limited, the nucleic acid, e.g., the genomic DNA of the tissue sample will preferably be subjected to amplification in order to allow extensive genetic testing. Sermon et al. (1996) and Cheung and Nelson (1996) describe a method of PCR-based amplification of isolated genomic DNA using partially or fully degenerated oligonucleotides, where the genomic DNA is isolated from cell biopsies. Equivalent methods are variations of the above protocols where oligonucleotides in combination with DNA polymerases are used without thermal cycling for the amplification of whole genome DNA like the method described by Dean et al. (2002).

A variety of suitable methods for whole genome amplification is published (for review see Lasken and Egholm, 2003; for details see Snabes et al., 1994; Sermon et al., 1996; Chrenek et al., 2000; Bannai et al., 2004). Alternatively or in addition, the tissue sample, e.g., the one or more, preferably two, cells isolated from the embryo or the non- human animal, are cultured in vitro under appropriate conditions in order to allow proliferation of such cells and thereby increasing the amount of tissue and nucleic acid derivable therefrom (see, e.g., Example 5).

4. Screening for the Presence of a Mutation

Screening for the presence of a mutation in a gene of interest may be performed on a single nucleic acid sample derived from the tissue sample as described herein, e.g., derived from one or more cells, preferably at least two cells, of an embryo or one or more cells from a non-human animal obtained in accordance with the invention. If using more than one cell of the non-human animal, these cells may derive from the same or different tissues or organs from said animal.

5 Alternatively, screening for the presence of a mutation in a gene of interest may be performed on a mixture or pool of nucleic acid samples derived from a plurality of the tissue samples as described herein. The plurality of said tissue samples may be, e.g., derived from a plurality of at least 4-cell stage embryos or non-human animals capable of sexually reproducing as described herein or from the offspring produced from the plurality i o of embryos and non-human animals obtained by the method of the invention.

Another embodiment of the invention includes screening for the presence of a mutation according to the invention in at least two genes of interest. This may be performed on a single nucleic acid sample. The nucleic acid sample may be derived from a tissue sample as described herein or a tissue sample derived from the offspring generations

15 of the embryos or the non-human animals obtained by the method of the invention. Alternatively, screening for the presence of a mutation according to the invention in at least two genes of interest may also be performed on a mixture of nucleic acid samples. The mixture of nucleic acid samples may be derived from a plurality of tissue samples as described herein, e.g., from a plurality of at least 4-cell stage embryos or a plurality of 0 non-human animals capable of sexually reproducing or the offspring generations of such embryos or non-human animals.

In yet another embodiment, a mutation in a gene of interest can be assigned to a particular phenotype in an individual, e.g., to a disease, after screening for the presence of a mutation in said gene of interest in an at least 4-cell stage embryo or a non- 5 human animal capable of sexually reproducing produced according to the methods of the invention. In a preferred embodiment, the individual is a human. Said embryo or non- human animal is preferably a mouse, rat, cattle, or pig.

A gene of interest is preferably a gene that is already known from an individual, e.g., a disease gene or an economically valuable gene. This information is then 0 used to produce an embryo or a non-human animal capable of sexually reproducing according to the methods of the invention. Such embryo or non-human animal or a plurality of embryos or non-human animals capable of sexually reproducing are used to isolate one or more cells, on which screening for the presence of a mutation in said gene of interest is performed. In a preferred embodiment, the individual is a human. Said embryo or non-human animal is preferably a mouse, rat, cattle, or pig. In another preferred embodiment, said individual is a non-human animal that is from the same species as said embryo or non-human animal produced according to the method of the invention.

The screening for the presence of a mutation in a gene of interest according to the invention may be performed by heteroduplex analysis. This analysis is based on detection of a base mismatch or base mismatches in a dsDNA molecule. Detection can be done either by non-denaturing gel electrophoresis or by using denaturing agents (gradients or constant concentrations) or temperature (gradients or constant temperature) in electrophoretic systems or liquid chromatography. Detection can also be done by chemical cleavage of the mismatch or mismatches using chemical agents as described by Cotton et al. (1988). Detection can further be done by proteins binding to the mismatch with or without subsequent cleavage of the double-standed (ds)DNA (reviewed in Nollau and Wagener, 1997). Equivalent methods are assays that exploit secondary structures of single stranded DNA or RNA molecules for the electrophoretic separation of nucleic acid strands that exhibit base variations as described by Orita et al. (1989), or assays for allele-specific hybridization to oligonucleotide-coated chips (for a review see Southern, 1996).

A specific example of a heteroduplex analysis is Temperature Gradient

Capillary Electrophoresis (TGCE). The amplified nucleic acid sample, e.g., the genomic DNA, is subject to PCR amplification according to standard methods in the art. Genomic DNA fragments of the gene of interest are obtained by PCR using BioTherm-DNA- Polymerase (GeneCraft, Germany) according to the manufacturer's protocol. Gene- specific oligonucleotide primers are designed using a publicly available primer design program (Primer3, www.genome.wo.mit.edu).

For detection of mutations in unknown positions in PCR-amplified DNA fragments of a gene of interest, dsDNA is electrophoresed through a temporal gradient of increasing temperature (Temperature Gradient Capillary Electrophoresis (TGCE); RevealSystem, SCE9610, by SpectruMedix LLC, State College, PA, USA). Because retardation of dsDNA during electrophoresis is greatest at the temperature of partial denaturation, DNA fragments of the same size can be separated according to their thermodynamic stabilities. Base mismatches within dsDNA molecules (heteroduplices) lead to a significant destabilization resulting in significant differences in melting temperatures (T_m) between heteroduplices and perfectly paired dsDNA (homoduplices). Such differences in T_m allow the separation of heteroduplices from homoduplices in a temperature gradient electrophoresis and serve as the basis for mutation detection by TGCE (cf. Example 6).

Alternatively, single strand conformation polymorphism (SSCP) or fluorescent SSCP (fSSCP) may be used as well as, e.g., Denaturing Gradient Gel Electrophoresis; Cleavage of Mismatches; Constant Denaturing Capillary Electrophoresis (CDCE); RNAse cleavage; Mismatch Repair detection; Mismatch Recognition by DNA repair enzyme; Sequencing by hybridization; Dot-blots; Reverse dot blots; Allele specific PCR; Primer-Induced Restriction analysis; Oligonucleotide Ligation; Direct DNA sequencing; Mini-sequencing; 5' Nuclease Assay; Representational Difference Analysis; or Microarrays, all described or referenced in WO 97/44485. Also, Denaturing High- Performance Liquid Chromatography (DHPLC) may be performed for mutation detection, as described in Liu et al., 1998.

Obviously, the screening methods according to the invention are not limited to the methods specifically described herein. Each method that may be useful in the connection with screening a mutation in a gene of interest may be employed.

Storing according to the invention may comprise any form and any duration of maintaining a fertilized oocyte, an embryo, cells of an embryo or of a non-human animal, or germ cells or nucleic acids as described herein. Long-term storage comprises storage for, e.g., a week, several weeks, a month, several months, or even a year or several years up to several decades. Short-term storage comprises storage, e.g., for several minutes, hours or days.

In one embodiment, embryos are stored, e.g., for reimplantation. Long-term storage may comprise freezing of the embryos. Protocols for freezing, such as cryopreservation, are applied to oocytes or to embryos at the pronucleate, cleavage or blastocyst stage of development and depend on the slow diffusion of the cryoprotectant through the zona pellucida (see Example 7). Protocols for the successful cryopreservation of biopsied embryos are established (see Lui et al., 1993; Nowshari and Brem, 2000a; Tominaga and Hamada, 2004, and Tominaga, 2004). Short-term storage may comprise the storing under appropriate culture conditions, e.g., in Ml 6 medium at 37°C and 5% CO₂, 5%O₂, and 90% N₂ (cf. Example 3).

The cells, which are stored in accordance with the invention may, e.g. comprise one or more cells of an embryo as described herein. Alternatively, such cells may comprise, e.g., one or more cells of a non-human animal, e.g., cells from its tissues or organs. For short-term storage, cells are kept in culture medium, e.g., for mouse blastomer cells in DMEM (Dulbecco's modified Eagle's medium; Invitrogen GmbH, Karlsruhe Germany), containing 15% FCS, 2 mM Glutamine, 0,1 mM β-mercaptoethanol, 50 mg/ml penicillin/streptomycin at 37°C, under 5% CO₂ and >90 % humidity in an incubator. For long-time storage, cells are kept frozen in a freezing medium, e.g., DMEM, containing 20% FCS, 10% DMSO.

The cells stored in accordance with the invention may also comprise germ cells, e.g., oocytes, spermatogonia, spermatides, or mature sperm cells as described herein. Long-term storage of such germ cells comprises, e.g., freezing. For freezing, e.g., mouse sperm cells, the males are aged between 3-5 month because the spermatozoa of younger males are sometimes less viable. Ideally, males are separated from each other two weeks before freezing, have proven fertility, and have not mated for more than one week. The male mice are sacrificed by cervical dislocation and the two caudae epididymides are dissected, removing as much fat as possible. The tissue is placed into 0.9% NaCl in the appropriate well of a 4-well dish (on ice) and washed in NaCl, i.e., all remaining fat and big blood vessels are removed with a watchmaker forceps and a spring scissors. Both caudae epididymides are placed into the cryoprotecting solution in the appropriate well of the 4-well dish (on ice). As few NaCl as possible is transferred. In the cryoprotecting solution each cauda epididymis and vas deferens is cut several times with a spring scissors. The 4-well dish is left on ice for approximately 1-2 minutes. In this time, the spermatozoa should disperse from the tissue (grey clouds). To get a homogeneous suspension, the dish is shaken carefully. The desired number of samples (e.g., 10 aliquots per 15 μl) is pipetted on to the Hd of the 4 well dish. A 1 ml syringe is connected with the French straw and approx. 100 μl HTF medium is aspirated alternately with one air bubble. The HTF medium just acts as a weight so that the straws will not float when they have to be plunged in liquid nitrogen. Both ends of the straw are welded. The samples are placed in a freezing canister and the freezing canister is put in the liquid vapor phase (-120⁰C) for 10 minutes (descending cooling rate of -20 to -4O⁰C per minute). After this time, the freezing canister is directly plunged in liquid nitrogen (-196⁰C) (Nakagata, 1993).

Another method of long-term storage of sperm cells is airdrying of sperm and subsequent fertilisation by ICSI (intracytoplasmatic sperm injection; see, e.g., Annual Meeting of the European Society of Human Reproduction and Embryology, Madrid, Spain, July 1, 2003).

In another embodiment, nucleic acids are stored. Long-term storage of nucleic acids may be performed by freezing the nucleic acids in an appropriate buffer, e.g., TE-buffer (10 mM Tris ph 7.5, 1 mM EDTA).

Fertilization

Fertilization of a mutated oocyte according to the invention comprises all types of fertilization feasible in the context of the methods described and claimed herein, e.g., fertilization ex vivo, such as the fertilization of zebrafish eggs and sperm, or in vitro fertilization (IVF), i.e., the incubation of oocytes with sperms outside of a non-human organism (cf., e.g., Example 2), or the incubation of oocytes after partial zona dissection

(PZD) with sperms outside of a non-human organism; the subzonal microinjection of sperm into the perivitelline space (SUZI); or the intracytoplasmic injection of a single sperm into an awaiting egg (ICSI).

Reimplantation

Reimplantation according to the present invention comprises the reimplantation or transfer of an embryo at its various developmental stages, e.g., zygotes, morulae, blastocysts. For example in mouse, embryos from the one cell to the morula stage (e.g., day 0.5 - 2.5 days post coitus (dpc)) can be transferred into the ampullae from the oviduct into a 0.5 dpc pseudopregnant foster mother, whereas 3.5 dpc blastocysts are transferred into the uterus horns of 2.5 dpc pseudopregnant foster mother (see also Example 8 and Manipulating the Mouse Embryo; 2003 A Laboratory Manual). Examples

EXAMPLE 1 : ENU Treatment of Non-Human Oocytes

Preparation of the ENU-Solution

ENU is dissolved in Soerenson Buffer, pH 6,0 for preparation of an ENU stock solution. For preparation of Soerenson buffer 9.078 g of KH₂PO₄ (Merck KgaA, Darmstadt, Germany), (Stock A), and 11.976 g Of Na₂HPO₄ (Merck KgaA, Darmstadt, Germany), (Stock B) is dissolved in each 1000 ml of distilled H₂O. 121 ml of Stock B solution is added to 879 ml of Stock A solution, mixed by inversion, and autoclaved. 1 g of ENU (Sigma Aldrich Chemie GmbH, Munich, Germany) is dissolved in 200 ml of Soerenson buffer by vigorous shaking for about 10 min. Final concentration is determined photospectrometrically and the ENU stock solution is continuously kept refrigerated.

Superovulation in Mouse

Three days before (day minus 3) ENU treatment and subsequent in vitro fertilization Intergonan (Intervet Deutschland GmbH; Unterschleissheim, Germany) is injected intraperitoneally (5 I.E./mouse; 0.1 ml/mouse) into oocyte donor females of mouse strain C3H. At day minus 1 Ovogest (Intervet Deutschland GmbH; Unterschleissheim, Germany) is injected intraperitoneally (5 I.EVmouse; 0.1 ml/mouse) into the same oocyte donor females.

Preparation of Oocyte Donor Mice

The oocyte donor females are sacrificed 14 hours after Ovogest injection. After disinfection with 70% alcohol, each mouse abdomen is opened with surgical scissors from caudal to cranial. The upper end of one uterine horn is grasped with fine forceps and the uterus, oviduct, ovary and the fad pad are removed. A hole is poked with the tip of a fine forceps into the membrane close to the oviduct, for further separation of the whole reproductive tract from the body wall. After stretching the whole reproductive tract and cutting between the oviduct and the ovary, the oviduct is finally removed. The whole procedure is repeated at the other uterine horn. Oviducts and the attached segments of the uterus are transferred into a pre-warmed culture dish, filled with lightweight paraffin oil (embryo tested; Sigma Aldrich Chemie GmbH, Munich, Germany). Oviducts from all the female mice are collected in one culture dish. Collected oviducts are transferred to a culture dish filled with 400μl of HTF medium (see in Quinn et al., 1985) the oviducts still being surrounded with oil. Under oil, the swollen ampullae are opened with the closed tip of fine forceps and the oocytes-cumulus complexes are expelled into the oil. A culture dish with oocytes-cumulus complexes is further subject to ENU treatment.

ENU Treatment of Isolated Mouse Oocytes

After removal of the HTF medium 500μl of an ENU/HTF solution is applied to the oocytes-cumulus complexes. Final ENU concentrations are in the range of 0.05 mg/ml to 5 mg/ml. The ENU/oocytes-cumulus suspension is incubated at 37°C in an incubator with an atmosphere of 5% CO₂ in air for 1 to 60 minutes, followed by washing twice in 500μl of HTF medium without ENU. The oocytes-cumulus complexes are transferred into a 40 mm culture dish filled with 500μl of fresh HTF medium and are covered with lightweight paraffin oil (embryo tested; Sigma Aldrich Chemie GmbH, Munich, Germany). Such treated oocytes are subject to in vitro fertilization, as described in Example 2.

EXAMPLE 2: Method of In Vitro Fertilization (IVF)

Sperm Isolation from Mice and Preparation

High quality mature sperms, i.e., spermatozoa, are collected from sexually reproducing male C3H mice, which had not been mated for at least 10 days. A male mouse is sacrificed by cervical dislocation, followed by immediate dissection oϊcauda epididymis and vas deferens. (Marschall et al., 1999).

After removal of fat tissue and blood vessels, both testis structures are washed briefly in 0.9% NaCl at room temperature, transferred into 500 μl of HTF fertilization medium (Quinn et al., 1985), and cut into 5 pieces allowing the sperms to flush out. Incubation in HTF medium is for 20 min. at 37⁰C in an incubator with an atmosphere of 5% CO₂ in air. For in vitro fertilization sperm is transferred into a fertilization dish. In Vitro Fertilization

Under microscopic examination and using a pipette with an 20 μl E-ART- tip (Molecular Bioproduct, San Diego, California, USA), the oocyte-cumulus complexes of Example 1 are transferred into the fertilization dishes containing isolated spermatozoa. Oocytes and spermatozoa are incubated for 4 to 6 hours in an incubator (37°C, 5% CO₂ in air), followed by removing from the incubator and subsequent washing of the oocytes of each fertilization dish (with the help of the silicon tube, mouth piece and the glass pipettes) for three times in a separate dish filled with 50 μl drops of KSOM medium (see in Lawitts and Biggers, 1991). Washing in drops of KSOM-medium was for removal of dead sperms and residues of the cumulus complex. After washing, the prepared oocytes are transferred into a fresh culture dish filled with 200 μl of KSOM-medium and are covered with equilibrated lightweight paraffin oil (equilibrated over night with KSOM-medium). For overnight incubation the culture dish is placed into an incubator adjusted to 37⁰C and an atmosphere of 5% CO₂ in air. The following day, the number of 2-cell embryos is examined microscopically. Only embryos displaying two symmetrical blastomeres are used for further culturing to an 8-cell embryo in 15 μl droplets of Ml 6 medium containing 5 mg/ml BSA and covered with lightweight paraffin oil (embryo tested; Sigma Aldrich Chemie GmbH; Munich, Germany). After culturing of the zygotes for approximately 48 h in an incubator at 37°C in an atmosphere containing 5% CO₂, 5% O₂, and 90% N₂, 8-cell embryos are observed.

EXAMPLE 3: Pre-Implantation Genetic Diagnosis (PGD) - Method of

Blastomer Dissection

Preparation of Materials

Blastomer dissection of a mouse 8-cell embryo may be performed according to a method described in Liu et al., 1993. In brief, zygotes are prepared as described in Example 2 and than cultured in 15 μl droplets of Ml 6 medium containing 5 mg/ml BSA and covered with lightweight paraffin oil (embryo tested; Sigma Aldrich Chemie GmbH; Munich, Germany). After culturing of the zygotes for approximately 48 h in an incubator at 37°C in an atmosphere containing 5% CO₂, 5% O₂, and 90% N₂, 8-cell embryos are observed. The removal of 2 blastomeres from an 8-cell embryo is performed under microscopic examination using an inverted microscope (Nikon, Tokyo, Japan). Holding and aspiration pipettes are made from 30 ml Drummond microcaps (Drummond Scientific Co., Broomall, PA, USA) on a model 753 Campden pipette puller (Campden Instruments Ltd., London, UK). The holding pipettes have an outer diameter of 60-80 μm and in inner diameter of 30-50 μm and are polished on a de Fonbrune microforge, pulled on the Campden pipette puller and then cut with the de Fonbrune microforge at the place where the outer diameter is 18-20 μm. A bevel angle of 45° is made with a Narishige 6-4 Microgrider. The inner diameter of the aspiration pipette is about 13-15 μm. The holding and aspiration pipettes are connected to 800 μl Narishige micrometer syringes by plastic tubing filled with lightweight paraffin oil.

Blastomer Dissection from Mouse Embryos

An 8-cell embryo is transferred into 10 μl of HTF collection medium droplets, kept under lightweight paraffin oil in 35 x 10 mm culture dishes at 37°C on a heated stage. The embryo is maintained in a stationary position by gentle suction through a holding pipette. The aspiration of the 2 blastomeres is done by puncturing the zona pellucida and by aspirating 2 blastomeres gently into the aspiration pipette. After the biopsy procedure, the manipulated embryos are transferred back to fresh Ml 6 medium and cultured in an incubator adjusted to 37°C and an atmosphere containing 5% CO₂, 5% O₂, and 90% N₂. Survival of the biopsy is assessed 1 h later under the inverted microscope at magnification of x 100 or x200. An embryo is considered to have survived the procedure if by inspection under the light microscope, all remaining blastomeres are intact. Such embryos are cryopreserved as described in Example 7. Dissected blastomer nucleic acid is subjected either to direct pre-implantation genetic diagnosis (see Example 4 and Example 6) or to in vitro culture (see Example 5) followed by pre-implantation genetic diagnosis as described in Example 4 and/or Example 6.

EXAMPLE 4: Pre-implantation Genetic Diagnosis (PGD) - Amplification of

Biopsy Genetic Material Primer Extension Preamplification (PEP) is used to amplify genomic DNA from single cell biopsies (see in Sermon et al. (1996). In brief, biopsy material is resupended in 5 μl alkaline lysis buffer (200 mM KOH, 50 mM dithiothreitol), heated to 65°C for 10 min. and neutralized by adding 5 μl neutralization buffer (900 mM Tris-HCl, pH 8.3; 300 mM KCl, 200 mM HCl). 5 μl of a 400 μM solution of random 15-base oligonucleotides are added (MWG Biotech AG, Ebersberg, Germany). In a random 15mer oligonucleotide any one of the four bases adenine, cytosine, guanine, and thymine could be present at each position. Following addition of 6 μl of PCR buffer (25 mM MgCVgelatin (1 mg/ml)/100 mM Tris-HCl, pH 8.3), 3 μl dNTP mixture (each 2 mM) and 1 μl Taq polymerase (GeneCraft, Germany; 5 units), the volume is raised to 60 μl with sterile water and 50 primer extension cycles are carried out in a MJ Research (Cambridge, MA) thermocycler. Each cycle consists of 1 min. denaturation at 94°C, 2 min. annealing at 37°C, a ramping step of 10 sec/degree to 55°C and a final 4 min. incubation step at 55°C. 3 to 8 μl of the first round PCR products are directly used for a second round of PEP, or for the amplification of myostatin gene sequences, as described in Example 6.

EXAMPLE 5: In Vitro Culture of Blastomeres Dissected From 8-Cell Embryos

As an alternative approach to generate a nucleic acid sample for PGD, both dissected blastomeres are directly transferred to one well of a gelatin-coated (0.2% gelatin (Invitrogen GmbH, Karlsruhe Germany) in PBS (Invitrogen GmbH, Karlsruhe Germany)) 96-well plate, each well filled with 100 μl of ES cell medium (DMEM (Dulbecco's modified Eagle's medium (Invitrogen GmbH, Karlsruhe Germany), containing 15% FCS, 2 mM Glutamine, 0.1 mM β-mercaptoethanol, 50 mg/ml penicillin/streptomycin). The cells are incubated at 37°C, under 5% CO₂ and >90% humidity in an incubator. Medium is changed daily until day 5, where the cells are washed with PBS and trypsinized with 30 μl of trypsin (Invitrogen GmbH, Karlsruhe Germany) for 5 min 37°C. Cells are resuspended in 150 μl ES cell medium before re-plating on one well of gelatin-coated 96-well plate. After four passages 1:1, the cells are plated on one well of a 24- well plate and cells are kept growing, ideally until confluency. The cells are trypsinized, resuspended in PBS buffer, collected by centrifugation (5 min. 100Ox g, Sigma clinical centrifuge), and resuspended in proteinase K buffer (0.5 M EDTA, 1 M Tris pH 9.5, 30% Sarkosyl, 20% SDS, Proteinase K 50 mg/ml (Sigma Aldrich Chemie GmbH, Munich, Germany)) for nucleic acid preparation. Nucleic acid is subjected to mutation detection (see Example 6).

EXAMPLE 6: Pre-Implantation Genetic Diagnosis (PGD) - Myostatin Mutation Detection by Heteroduplex Analysis Using

Temperature Gradient Capillary Electrophoresis (TGCE)

For detection of heterozygous mutations in nucleic acid from tissue samples, genomic DNA is used to PCR amplify DNA fragments of the myostatin gene with myostatin-specific PCR primers. The following primer pairs Mst-1 and Mst-2, Mst-3 and Mst-4, and Mst-5 and Mst-6 were designed for the amplification of the individual exons in PCR amplification reactions:

Standard PCR reactions (total volume: 20 μl) are carried out using amplified biopsy genomic DNA of M. musculus strain C57/B16 as template. The genomic DNA derives from a tissue sample and is either directly used for PCR; or previously enriched by Primer Extension Pre-amplification (see Example 4); or previously in vitro cultured for sample material enrichment (see Example 5), or both.

Upon initial denaturation at 94°C for 3 min. each cycle consisted of a 30 sec. denaturation step at 94°C, a 30 sec. annealing step at 56°C and a 45 sec. synthesis step at 72°C. 40 cycles are carried out in a MJ Research (Cambridge, MA) thermocycler. Following PCR amplification, hybrids of wild type and mutant DNA strands are formed in a denaturation/renaturation step, transforming base pair exchanges into heteroduplices with lower thermal stability. A typical temperature profile for denaturation/renaturation is:

heat sample to 95°C and hold for 5 min.

decrease from 95°C to 8O⁰C at 3°C/min.

decrease from 80°C to 55°C at l°C/min.

hold 20 min. at 55°C

decrease from 55°C to 45°C at l°C/min.

decrease from 45°C to 25°C at 2°C/min.

Depending on the DNA concentration obtained in the PCR reaction the sample is diluted in a range of 1:10 to 1:50 and subjected to TGCE, as described by Li et al. (2002). Washing, dilution and running buffers are supplied by the manufacturer. Typical operation parameters for TGCE are:

Prerun: 25 min.

Injection voltage: 3-8 kV

Injection time: 3-10 sec.

Running voltage: 10 kV

Electrophoresis time: 60 min.

The applied temperature gradient during electrophoresis depends on the base composition (G+C content) of the analyzed fragment and ranges from 55°C to 7O⁰C.

Upon completion the obtained electrophoresis pattern is analyzed for additional bands resulting from decreased mobility of heteroduplices during TGCE, using the manufacturers software program Revelation 2.10. Candidate fragments are further analyzed by DNA sequencing. To this end, PCR products amplified with primers specific for the myostatin gene are purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. PCR products are sequenced using forward/reverse PCR primers and the "Big Dye" thermal cycle sequencing Kit (ABI PRISM, Applied Biosystems, Foster City, CA, U.S.A.)- The reaction products are analyzed on an ABI 3700 DNA sequencing device.

The sequences are edited manually and different sequence fragments are assembled into one contiguous myostatin sequence using the software Sequencer version 4.0.5. (Gene Codes Corp., Ann Arbor, MI, U.S.A.). The myostatin gene of a heterozygous ENU embryo and of a wild type embryo is sequenced. The sequencing results are used to identify mutations by comparing the sequencing results from embryos carrying the ENU mutation with wild-type embryos.

EXAMPLE 7: Cryopreservation of Non-Human Embryos (Frozen Embryo

Archive)

Rapid-freezing of biopsied mouse embryos (6-cell dissected embryo) is performed by a method described in Liu et al., 1993. hi brief, 6-cell dissected embryos, grown from in vitro fertilized eggs as described in Example 2 and dissected as described in Example 3, are cryopreserved by a slow freezing procedure with 1.5 M 1 ,2-proρanediol (PROH) adapted from the procedure described by Lasalle et al., 1985. The cryoprotectant solution is prepared by adding 1.5 M PROH (Fluka AG, VeI, Leuven, Belgium) and 0.1 M sucrose (British Drug House) to M2 medium. The cryoprotectant mixture is cooled on crushed ice. A single biopsied embryo is transferred into 30 μl of the cold cryoprotectant mixture and then transferred into 0.25 ml plastic straws (Type - 2 A 175, Industrie de Ia Medecine Veterinaire, L'Aigle, France). The straws are carefully labeled and put into the freezing chamber of a programmable biological freezer (Planer R294, HVL, Brussels, Belgium) that has been pre-cooled to 0⁰C. The straws are kept for 15 min. at 0°C and then cooled to -6°C at a cooling rate of -2°C/min. The induction of the extracellular ice crystal formation is done at -6°C by touching the straw with forceps cooled in liquid nitrogen. The embryo is further cooled at -30⁰C at a cooling rate of- 0.3°C/min. The embryo straw is then plunged into liquid nitrogen. For thawing of the embryo the plastic straw is taken out of the storage bank and transferred to a water bath at 37°C. The thawing rate is approximately 600°C/min. The thawed cryoprotectant mixture with the embryo is transferred into a culture dish containing 100 μl droplets of collection medium with 1.0 M sucrose. The cryoprotectant is removed by incubating the embryo for 10 min. in collection medium with 1.0 M sucrose and for 10 min. in collection medium without sucrose. Thereafter the embryo is rinsed several times in collection medium and transferred into M 16 culture medium droplets under lightweight paraffin oil. Droplets, containing the embryos, are then kept in an incubator at 37°C in an atmosphere containing 5% CO₂, 5% O₂, and 90% N₂. The survival after freezing and thawing is assessed after about 1 hour of in vitro culture under an inverted microscope at x200 or x400 magnification. Embryos are considered to have survived the procedure if they contain the same number of blastomeres with the zona pellucida intact, as they do before the cryopreservation.

EXAMPLE 8: Embryo Transfer

Production of Mouse Pseudo-Pregnant Females

Pseudo-pregnancy is generated by mating mouse CDl females (8-10 weeks of age, at a body weight of approximately 30 g) to vasectomized or genetically sterile males. It is recommended to mate at least 10 females per one scheduled embryo transfer, with each two females mated over night to one vasectomized male. A vaginal plug is visible the next morning after coitus.

Uterus Transfer

An embryo for embryo transfer is selected depending on the result of pre- implantation genetic diagnosis. Before the transfer, a thawed embryo of Example 7 is washed two times in M2 Medium and subsequently stored in one drop of M2 medium covered with lightweight paraffin oil (embryo tested; Sigma Aldrich Chemie GmbH, Munich, Germany) on a warming plate at 37°C. For the transfer, a pseudo-pregnant female mouse is anaesthetized by intra-peritoneal injection of 0.25 ml anesthetic (Rompun 2%/Ketamin 5%). Reflexes of the anaesthetized mouse are tested by pricking the tail and foot pads gently with forceps 5 minutes after anaesthetizing. During this time, the embryo is prepared for the transfer. Under microscopic examination, an visually intact 6 cell embryo is collected with a transfer pipette in approximately 50 μl of M2 medium. 5 minutes after anesthetic injection the mouse is placed onto the lid of a 140 mm culture dish, and her back is disinfected with 70% alcohol. A first small transverse incision is made to the skin (approx. 1 cm to the left side of the spinal cord, at the level of the last rib), the peritoneum is opened with fine scissors, the fad pad is picked up, and ovary, oviduct and the uterus horn are pulled out with fine forceps. This tissue complex is fixed on the fad pad with the help of a bullock clamp, located on the back of the mouse. The mouse is placed on the stage of a light microscope (head on the left side, tail to the right side).

To achieve successful embryo transfer in general, it is necessary to transfer more than one embryo into the uterus of one pseudo-pregnant female mouse. Therefore, in addition to the embryo selected based on the result of a pre-implantation genetic diagnosis, five to ten 8 cell-stage embryos (blastocyst embryos of the mouse strain C57BL/6J are co- transferred into the uterus of such pseudo-pregnant female mouse. These co-transferred embryos are generated by IVF according to Example 2, using sperm cells and oocytes of wildtype C57BL/6J mice.

Under microscopic examination the top of the uterus is gently lifted with blunt fine forceps and a small hole is made into the uterus, a few millimeters down from the utero-tubal junction, using a 26 gauge needle. The prepared transfer pipette containing the blastocyst embryos, including a single 6 cell-stage embryo carrying a mutation in a gene of interest and several 8 cell-stage wildtype embryos, is inserted into the hole and the embryos are expelled into the uterus. The bullock clamp is undipped and ovary and oviduct are carefully returned into the abdomen. The body wall is closed with one stitch, the skin is closed with a wound clip. All steps are repeated for the right oviduct of the same mouse. After surgery the mouse is left undisturbed on a warming plate for approx. 10 min. until waking it up.

Foster mothers are kept until offspring is born. Offspring is subject to further phenotypic and molecular genetic analysis. Mutant and wildtype embryos are visibly distinguishable by their different coat colors. References

Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabel JW, Soos MA, Li Maslen G, Williams TDM₅ Lewis H, Schafer AJ, Chatterjee VKK, and O'Rahilly S, 1999. Dominant negative mutations human PP ARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883.

Bannai M, Higuchi K, Akesaka T, Furukawa M, Yamaoka M, Sato K, and Tokunaga K, 2004. Single-nucleotide-polymorphism genotyping for whole-genome- amplified samples using automated fluorescence correlation spectroscopy. Anal Biochem., 327(2):215-221.

Betsch, DF. Pharmaceutical production from transgenic animals. http://www.biotech.iastate.edu/biotech info series/bio lO.html, Office of Biotechnology, Iowa State University.

Bondioli KR, Ellis SB, Pryor JH, Williams MW, and Harpold MM, 1989. The use of male specific chromosomal DNA fragment to determine the sex of bovine peimplantation embryos. Theriogenology 31 :95— 104.

Bradley A, Evans M, Kaufrnann MH, and Robertson E, 1984. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature, 1984, 309:255-256.

Bredbacka P, Velmala R, Peippo J, Bredbacka K, 1994. Survival of biopsied and sexed bovine demi-embryos. Theriogenology, 41 : 1023-1031.

Capecchi MR, 1989. Altering the genome by homologous recombination. Science, 1989, 244:1288-1292.

Cheung VG, Nelson SF: Whole genome amplification using a degenerate oligonucleotide primer allows hundreds of genotypes to be performed on less than one nanogram of genomic DNA. Proc Natl Acad Sci U S A. 1996 Dec 10;93(25): 14676-9

Chrenek P, Boulanger L, Heyman Y, Uhrin P, Laurincik J, Bulla J, and Renard JP, 2001. Sexing and multiple genotype analysis from a single cell of bovine embryo. Theriogenology., 55(5): 1071-1081. Cotton RG, Rodrigues NR, Campbell RDiReactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4397- 401.

Dean FB, Hosono S, Fang L, Wu X, Faruqi AF, Bray-Ward P, Sun Z, Zong

Q, Du Y, Du J, Driscoll M, Song W, Kingsmore SF, Egholm M, Lasken RS: Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6.

Deen A, Vyas S, Sahani MS. Semen collection, cryopreservation and artificial insemination in the dromedary camel. Anim Reprod Sci. 2003 JuI 15;77(3- 4):223-33.

Foote RH, Kaprotht MT. Large batch freezing of bull semen: effect of time of freezing and fructose on fertility. J Dairy Sci. 2002 Feb;85(2):453-6.

Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, and Bhasin S., 1998. Organization of the human myostatin gene and expression in healthy men and HIV- infected men with muscle wasting. Proc Natl Acad Sci U S A. 1998, 95(25):14938-14943.

Grunwald DJ and Streisinger G, 1992. Induction of recessive lethal specific locus mutations in the zebrafish with ethyl nitrosourea. Genetic Research, 1992, 59(2):103-116.

Handyside AH and Delhanty JD, 1997. Preimplantation genetic diagnosis: strategies and surprises. Trend Genet., 13(7):270-275.

Hitotsumachi S, Carpenter DA, Russell WL, 1985. Doese-repitition increases the mutagenic effectiveness of N-ethyl-N-nitrosourea in mouse spermatogonia. PNAS 82(19): 6619-6621.

Hughes GC, Biswas SS, Yin B, Coleman RE, DeGrado TR, Landolfo CK, Lowe JE, Annex BH, Landolfo KP. Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thorac Surg. 2004 Mar;77(3):812-8. Kurahashi M, Miyake H, Takagi T, Tashiro S. Changes of lymphatic flow in case of pancreatic duct obstruction in the pig— as a model of pancreatic cancer. J Med Invest. 2004 Feb;51(l-2):70-5.

Lai L, Kolber-Simonds D, Park KW, Cheong HT, Greenstein JL, Im GS, Samuel M, Bonk A, Day BN, Murphy CN, Carter, DB, Hawley RJ, Prather RS, 2002. Production o alpha-l,3-galactosyltransferase knockout pigs by nuclear transgfer cloning. Science 295:1089-1092.

Lasken RS, Egholm M, 2003. Whole genome amplification: abundant supplies of DNA from precious samples or clinical specimens. Trends Biotechnol., 21(12):531-535.

Lasalle B, Testart J and Renard JP, 1985. Human embryo features that influence the success of cryopreservation with the use of 1,2-propanediol. Fertil. Steril., 44:645-651.

Lawitts JA, Biggers JD, 1991. Optimization of mouse embryo culture media using simplex methods. J Reprod Fertil., 91(2):543-556.

Li Q, Liu Z, Monroe H, Culiat CT, 2002. Integrated platform for detection of DNA sequence variants using capillary array electrophoresis. Electrophoresis May;23(10):1499-511.

Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, and James CD, 1998. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acid Research 26(6): 1396-1400.

Liu J, Van den Abbeel E, and Van Steirteghem A, 1993. The in-vitro and in-vivo developmental potential of frozen and non-frozen biopsied 8-cell mouse embryo. Hum Reprod , 8(9):1481-1486.

Magyary, I, Urbanyi, B and Horvath, L: Cryopreservation of common carp

(Cyprinus carpio L.) sperm I. The importance of oxygen supply. Journal of Applied Ichthyology, 12 , 1 13-1 15, 1996. Mandel NS, Henderson JD Jr, Hung LY, Wille DF, Wiessner JH. A porcine model of calcium oxalate kidney stone disease J Urol. 2004 Mar; 171 (3): 1301 -3.

Manipulating the Mouse Embryo; 2003 A Laboratory Manual, Third Edition; Cold Spring Harbor Laboratory Press.Marschall S, Huffstadt U, Balling R, Hrabe de Angelis M, 1999. Reliable recovery of inbred mouse lines using cryopreserved spermatozoa. Mammalian Genome 10(8):773-776.

Moody R, Davis SW, Cubas F, Smith WC, 1999. Isolation of developmental mutants of the ascidian Ciona savignyi. MoI Gen Genet, 1999, 262(1):199- 206.

Nakagata N., 1993. Production of normal young following transfer of mouse embryos obtained by in vitro fertilization between cryopreserved gametes. J Reprod Fertil. 1993 Sep;99(l):77-80.

Nollau P, Wagener C.:Methods for detection of point mutations: performance and quality assessment. IFCC Scientific Division, Committee on Molecular Biology Techniques. Clin Chem. 1997 Jul;43(7):l 114-28.

Noverskoe JK, Weber JS, and Justice MJ, 2000. The mutagenic action of N-ethyl-N-nitrosourea in the mouse. Mammalian Genome 11 :478-483.

Nowshari MA, and Brem G, 2000a. Refreezing of murine intact and biopsied embryos by rapid-freezing procedure. Hum Reprod., 15(12):2577-2581.

Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T.: Detection of polymorphisms of human DNA by gel electrophoresis as single-strandconformation polymorphisms. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2766-70.

Quinn P, Kerin JF, Warnes GM, 1985. Improved pregnancy rate in human in vitro fertilization with the use of a medium based on the composition of human tubal fluid. Fertil Steril., 44(4):493-498.

Phelps CJ, Koike C,, Vaught TD, Boone J, Wells KD, Chen SH, Ball S, Specht SM, Polejaeva IA, Monahan JA, Jobst PM, Sharma SB, Lamborn AE, Garst AS, Moore M, Denetris AJ, Rudert WA, Bottino R, Bertera S, Trucco M, Starzl TE, Dai Y, Ayares DL, 2003. Production of alpha-l^-galactosyltransferase-deficient pigs. Science 299:411-414.

Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M. Wilmut I, Colman A, and Campbell KHS. 1998. Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science, 1998, 278:2130- 2133.

Sermon K, Lissens W, Joris H, Van Steirteghem A, and Liebaers I, 1996. Adaptation of the primer extension preamplification (PEP) reaction for preimplantation diagnosis: single blastomere analysis using short PEP protocols. MoI Hum Reprod.,2(3):209-212.

Snabes MC, Chong SS, Subramanian SB, Kristjansson K, DiSepio D, and Hughes MR, 1994. Preimplantation single-cell analysis of multiple genetic loci by whole- genome amplification. ProcNatl Acad Sci U S A., 91(13):6181-6185.

Southern EM: DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. Trends Genet. 1996 Mar;12(3):l 10-5.

Russ A, Stumm G, Augustin M, Sedlmeier R, Wattler S, and Nehls M, 2002. Random mutagenesis in the mouse as a tool in drug discovery. Drug Discovery today 7(23):1175-1183.

Takeuchi K, Snadow BA, Morsy M, Kaufrnann RA, Beebe SJ, and Hodge GD, 1992. Preclinical models for human pre-embryo biopsy and genetic diagnosis. I. Efficiency and normalcy of mouse pre-embryo development after different biopsy techniques. Fertil Steril.,57(2):425-430.

Tominaga K, and Hamada Y, 2004. Efficient production of sex-identified and cryosurvived bovine in- vitro produced blastocysts. Theriogenology, 61 (6): 1181-91.

Tominaga K, 2004. Cryopreservation and sexing of in vivo- and in vitro- produced bovine embryos for their practical use. J Reprod Dev., 50(l):29-38.

Vogel EW and Natarajan AT, 1995. DNA damage and repair in somatic and germ cells in vivo. Mutation Research, 1995, 330(l-2):183-208. West JD, Frels WI, Papaioannou VE, Karr JP, and Chapman VE, 1977. Development of interspecific hybrids of Mus. J. Embryol. Exp. Morph, 41 :233-243.

Claims

Claims

1. A method of providing an oocyte capable of producing a mutated non-human animal comprising:

(a) treating an oocyte with a mutagen in vitro;

(b) contacting the oocyte obtained in step (a) with a sperm cell for fertilization.

2. The method of claim 1, further comprising storing of the fertilized oocyte of step (b).

3. A method of providing an embryo capable of producing a mutated non-human animal comprising:

(a) treating an oocyte with a mutagen in vitro;

(b) contacting the oocyte obtained in step (a) with a sperm cell for fertilization and allowing the resulting zygote to develop into: (i) an at least 4-cell stage embryo; or

(ii) a non-human animal capable of sexually reproducing.

4. A method according to any one of claims 1 to 3, wherein the sperm cell of step (b) was not treated with a mutagen.

5. A method according to claims 3 or 4, further comprising storing the embryo or one or more germ cells of the non-human animal obtained in step (b).

6. A method according to claims 3 or 4, further comprising maintaining the non-human animal obtained in step (b).

7. The method according to any one of claims 1 to 6, wherein the mutagen is a chemical or physical mutagen.

8. The method of claim 7, wherein said chemical mutagen is selected from the group consisting of N-ethyl-N-nitrosourea (ENU), Methylnitrosourea (MNU), Procarbazine hydrochloride (PRC), Triethylene melamine (TEM), Acrylamide monomer (AA), Chlorambucil (CHL), Melphalan (MLP), Cyclophosphamide (CRP), Diethyl sulphate (DES), Ethyl methane sulphonate (EMS), Methyl methane sulphonate (MMS), 6-mercaptopurine (6MP), Mitomycin-C (MMC), Procarbazine (PRC), N- methyl-N-nitro-N-nitrosoguanidine (MNNG), N-nitrosodiethylamine (NDEA),

Isopropyl methane sulphonate (iPMS), ³H₂O, Urethane (UR), Bleomycine, Nitrogen Mustard, Vincristine, Dimethylnitrosamine, 7,12-Dimethylbenz(a)anthracene (DMBA), Ethylene oxide, Hexamethylphosphoramide, Bisulfan, Acridine orange, Ethidium bromide, Proflavin, and ICR-191.

9. The method of claim 7, wherein said physical mutagen is selected from gamma- radiation, X-ray radiation, UV-light, and neutrons.

10. The method according to any one of claims 1 to 9, wherein said oocyte and said sperm cell are derived from the same non-human animal species.

11. The method according to any one of claims 1 to 9, wherein said oocyte and said sperm cell are derived from different non-human animal species.

12. The method according to any one of claims 1 to 11, wherein said oocyte, said sperm cell or both are derived from a transgenic non-human animal.

13. The method according to any one of claims 1 to 11, wherein said oocyte, said sperm cell, or both are derived from a wild-type non-human animal.

14. The method according to any one of claims 1 to 13, wherein said fertilization comprises in vitro fertilization.

15. The method of any one of claims 5 or 7 to 14, wherein the embryo stored is a morula or a blastocyst.

16. The method of any one of claims 5 or 7 to 14, wherein the one or more germ cells are selected from ooyctes, spermatogonia, spermatides, and mature sperm cells.

17. The method of any one of claims 3 to 16, wherein the method further comprises the isolation of one or more, preferably at least two, cells of the embryo or the non- human animal.

18. The method of claim 17, wherein said one or more cells or said at least two cells of the embryo or the non-human animal are isolated prior to the storing of claim 5.

19. The method of any one of claims 3 to 18, wherein the method further comprises the screening of a nucleic acid sample derived from one or more, preferably at least two, cells of the embryo or the non-human animal produced in step (b) for the presence of a mutation in a gene of interest.

20. The method of claim 19, wherein said one or more or said at least two cells are the cells isolated according to claims 17 or 18.

21. The method according to any one of claims 17 to 20, wherein the one or more or the at least two cells of the embryo are blastomeres or trophoectodermal cells.

22. The method according to any one of claims 17 to 20, wherein the one or more cells of the non-human animal derive from an organ or a tissue.

23. The method of claim 22, wherein said tissue is ear or tail tissue or said organ is liver.

24. The method according to any one of claims 19 to 23, wherein the nucleic acid sample is RNA or DNA.

25. The method of claim 24, wherein the DNA is genomic DNA.

26. The method according to any one of claims 19 to 25, wherein the screening method comprises a PCR specific for the gene of interest; Heteroduplex Analysis, e.g., Temperature Gradient Capillary Electrophoresis (TGCE); Single Strand Conformation Polymorphism (SSCP); Denaturing High Performance Liquid

Chromatography (DHPLC); fluorescent Single Strand Conformation Polymorphism (fSSCP); Denaturing Gradient Gel Electrophoresis (DGGE); Cleavage of Mismatches; Constant Denaturing Capillary Electrophoresis (CDCE); RNAse cleavage; Mismatch Repair detection; Mismatch Recognition by DNA repair enzyme; sequencing by hybridization; dot-blots; reverse dot blots; allele specific

PCR; Primer-Induced Restriction analysis; Oligonucleotide Ligation; Direct DNA sequencing; Mini-sequencing; 5' Nuclease Assay; Representational Difference Analysis; or Microarrays.

27. The method according to any one of claims 19 to 26 further comprising the step of amplifying the nucleic acid sample by PCR.

28. The method according to any one of claims 19 to 27 further comprising culturing said one or more or said at least two cells of the embryo or the non-human animal in vitro under appropriate conditions to allow cell proliferation prior to screening.

29. The method according to any one of claims 19 to 28 further comprising the step of assigning said mutation to the corresponding stored embryo, the one or more germ cells of the non-human animal stored according to claim 5, or to the non-human animal maintained according to claim 6.

30. The method according to any one of claims 5 or 7 to 29, wherein said storing is performed by freezing or by storing in an appropriate culture medium or, in case the stored germ cells are sperm cells, by freeze drying.

31. The method according to any of claims 1 or 7 to 14, wherein step (b) comprises contacting a plurality of oocytes obtained in step (a) with sperm cells for fertilization and wherein the storing of claim 2 comprises the storing of a plurality of the fertilized oocytes obtained in step (b).

32. The method according to any one of claims 3 to 30, wherein step (b) comprises contacting a plurality of oocytes obtained in step (a) with sperm cells for fertilization, and allowing the resulting zygotes to develop into at least 4-cell stage embryos or non-human animals capable of sexually reproducing, and wherein:

(i) the storing of claim 5 comprises storing a plurality of the embryos or the germ cells of the non-human animals obtained in step (b); or (ii) the maintaining of claim 6 comprises maintaining a plurality of the non-human animals obtained in step (b).

33. An archive comprising the stored oocytes, embryos or germ cells of the non-human animals obtained by the methods of claims 31 or 32.

34. The archive of claim 33, wherein said storing is performed by freezing or by storing in an appropriate culture medium or, in case the stored germ cells are sperm cells, by freeze drying.

35. The archive of claims 33 or 34, wherein said embryos are morulas.

36. The archive of claims 33 or 34, wherein said embryos are blastocysts.

37. The archive of claims 33 or 34, wherein said germ cells are selected from oocytes, spermatogonia, spermatides, and mature sperm cells.

38. An archive comprising the maintained non-human animals obtained by the method of claim 32.

39. Use of the oocyte(s), embryo(s) or the germ cell(s) obtained or obtainable by the method of any one of claims 1 to 32 or of the archive of any one of claims 33 to 37 for producing a non-human animal.

40. A method of producing a non-human animal comprising allowing the embryo obtained or obtainable by the method of any one of claims 3 to 30 or an embryo of the archive of any one of claims 33 to 36 to develop into a non-human animal.

41. A method of producing a non-human animal comprising allowing the germ cells of the non-human animal obtained or obtainable by the method of any one of claims 5 to 30 or the germ cells of the archive of any one of claims 33, 34 or 37 to develop into a non-human animal.

42. The use or the method according to any one of claims 39 to 41, wherein the non- human animal is non-transgenic.

43. The use or the method according to any one of claims 1 to 42, wherein the non- human animal is a vertebrate.

44. The use or the method of claim 43, wherein said vertebrate is a mammal, a fish, or a bird.

45. The use or the method of claim 44, wherein said mammal is selected from the group consisting of mouse, rat, hamster, rabbit, cattle, pig, guinea pig, sheep, goat, horse, camel, dog, cat, and monkey, e.g., rhesus macaque, baboon, orang-utan, and chimpanzee.

46. The use or the method of claim 44, wherein said bird is selected from the group consisting of chicken, duck, turkey, goose, pigeon, and Japanese quail.

47. The use or the method of claim 44, wherein said fish is selected from the group consisting of salmon, trout, tilapia, carp, catfish, medaka, zebrafish, loaches, goldfish

5 and pikes.

48. The use or the method according to any one of claims 39, 40, or 42 to 47 comprising the reimplantation of the embryo, preferably a morula or a blastocyst stage, into a non-human animal foster mother.

49. The use or the method according to any one of claims 39, or 41 to 47, wherein the i o one or more germ cells are sperm cells, and wherein said method comprises:

(a) in vitro fertilization of an oocyte with said one or more sperm cells of the non-human animal and the subsequent reimplantation of the resulting embryo into a non-human animal foster mother; or

(b) artificial insemination with said one or more sperms of a non-human 15 animal.

50. The use or the method according to any one of claims 39 to 49, wherein a plurality of non-human animals are produced from the embryos or germ cells stored in (i) or maintained in (ii) of the method of claim 32 or from the stored oocytes of claim 31.

51. The use or the method according to any one of claims 3 to 30, 32 or 38 to 50, further 0 comprising breeding of the (maintained) non-human animal(s) to produce a plurality of offspring generations.